lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
1,156 rows where filing_year = 2018 and issue_code = "PHA" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2101605 | HOLLAND & KNIGHT LLP bbc93648-c4b8-4d91-896d-3c6dcb937ff8 | Q1 | HOLLAND & KNIGHT LLP | 18466 | THE BIOSIMILARS FORUM | 2018 | first_quarter | PHA | Medicare reimbursement issues, FDA regulation of biosimilars; H.R. 1625, Consolidated Appropriations Act of 2018. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 120000 | 0 | 0 | 2018-04-02T14:15:27.313000-04:00 | |
| 2101608 | HOLLAND & KNIGHT LLP f8f1c435-d277-4277-933e-b420086e1308 | Q1 | HOLLAND & KNIGHT LLP | 18466 | PROTECTING ACCESS TO PAIN RELIEF COALITION | 2018 | first_quarter | PHA | Advocating for policy to ensure patient access to pain relief; H.R. 664, Stop OD Act of 2017; S.1554, Safer Prescribing of Controlled Substances Act; H.R. 3964, Opioid Addiction Prevention Act of 2017; H.R. 2063, Opioid PACE Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-04-02T14:22:30.077000-04:00 | |
| 2101767 | MS. TAMI WAHL 6736cab0-1b17-4797-8ebc-7041c21e7d11 | Q1 | MS. TAMI WAHL | 401104405 | ROCK & ASSOCIATES | 2018 | first_quarter | PHA | Legislation impacting the operation of pharmacy compounding, and access to compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2018-04-03T08:17:03.813000-04:00 | |
| 2102021 | AMERICAN COLLEGE OF CLINICAL PHARMACY 881c774b-1fff-4ebc-a9ec-dca34b11e495 | Q1 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2018 | first_quarter | PHA | Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 144981 | 0 | 0 | 2018-04-04T11:26:16.370000-04:00 | |
| 2102350 | CHATMAN, LLC 95364518-a789-4e03-8d82-eda75c631163 | Q1 | CHATMAN, LLC | 400678024 | LIVINGSTON GROUP FOR RUSH UNIVERSITY MEDICAL CENTER | 2018 | first_quarter | PHA | Support continuation of Pharmacy 340B program in HRSA. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2018-04-05T22:28:42.850000-04:00 | |
| 2102406 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 3b892256-655d-4d61-aa8c-0a4181ebec2f | Q1 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 401103605 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 2018 | first_quarter | PHA | Lobbied for OTC Monograph Reform bill, answered questions about opioid manufacturing/packaging, discussed potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-04-06T10:18:42.090000-04:00 | |
| 2102509 | RED+BLUE STRATEGIES a31e9579-befa-4e13-8edc-29120d4b4892 | Q1 | RED+BLUE STRATEGIES | 400693064 | EXPRESS SCRIPTS INC. | 2018 | first_quarter | PHA | H.R. 1625/PL 115-141 - Consolidated Appropriations Act of 2018 - Issues related to access to and affordability of prescription medications and inclusion of tools to fight the opioid epidemic. H.R. 1301/PL 115-124 - Continuing Resolution of 2018 - Issues related to access to and affordability of prescription medications and policies and resources to fight the opioid crisis in the United States. CMS regulations regarding the Part D program and the role of prescription drug plans. S. 637 - Creating Transparency to have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A bill to Improve Access to Affordable Prescription Drugs - Issue related to bringing drug pricing down including better policies in the Part D coverage gap, couponing and advancing biosimilars. H.R. 281- National Defense Authorization Act for FY 2018- Issues related to prescription medications for military personnel and their families. H.R. 3447 - Furthering Access to Coordinated Treatment for Seniors (FACTS) Act of 2017 - Working to explain the need for safe and confidential data sharing between Medicare part A, B, and D to ensure better coordination of patient care. Issues related to Direct and Indirect Renumeration policies and their impact on consumers. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2018-04-06T14:05:22.117000-04:00 | |
| 2102542 | RED+BLUE STRATEGIES 40ae77a2-61f3-4e92-889c-c90dad2c92f0 | Q1 | RED+BLUE STRATEGIES | 400693064 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2018 | first_quarter | PHA | H.R. 1625/PL 115-141 - Consolidated Appropriations Act of 2018 - Issues related to access and affordability of prescription medications and policies to combat the opioid crisis in the United States. H.R. 1301/PL 115-124 - Continuing Resolution of 2018 - Issues related access and affordability of prescription medications in the United States, treatment of biosimilars and generics in public and private insurance and policies to combat the opioid crisis in the United States. CMS Regulations related to the Medicare Part D program and Prescription Drug Plans (PDPs) S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies. Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D. Issues related to lowering the price of prescription medications in the United States. | HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office | 60000 | 0 | 0 | 2018-04-06T15:08:50.833000-04:00 | |
| 2102546 | RED+BLUE STRATEGIES 74fad7c9-b64b-40ff-bf1d-01f2005585b0 | Q1 | RED+BLUE STRATEGIES | 400693064 | PEW CHARITABLE TRUSTS | 2018 | first_quarter | PHA | H.R. 1625/PL 115-141 - Consolidated Appropriations Act of 2018 - Issues related to policies regarding antibiotic resistance, compounding, policies surrounding access to prescription medications and policies to combat the opioid crisis in the United States. H.R. 1301/PL 115-124 - Continuing Resolution of 2018 - Issues related access and affordability of prescription medications in the United States, treatment of biosimilars and generics in public and private insurance and policies to combat the opioid crisis in the United States. CMS regulations related to Medicare Part D and promulgation of laws related to curbing substance use disorder among Medicare beneficiaries. S. 1334/H.R. 2797 - Patient Choice and Quality Care Act of 2017 - Issues related to better integration of end-of-life and palliative care into the nation's health care system. H.R. 2871 - The Preserving Patient Access to Compounded Medications Act of 2017 - Concerns about how the bill could compromise safety protocols for compounded medications. Issues related to antibiotic innovation and advancement Issues related to monograph reform. Issues related to health information technology, unique device identifiers on Medicare claims forms, and other critical policies to promote device safety. Issues related to over the counter medications and supplements. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-04-06T15:25:52.453000-04:00 | |
| 2103189 | KATE MOSS d04d969c-bb1b-44e8-be64-787ad016430e | Q1 | KATE MOSS | 25988 | CVS HEALTH | 2018 | first_quarter | PHA | Legislation impacting PBMs and drug pricing | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2018-04-10T11:08:34.323000-04:00 | |
| 2103310 | INDEPENDENT PHARMACY COOPERATIVE 3bd7e7ac-d45f-4c97-962b-b74b827d5ea2 | Q1 | INDEPENDENT PHARMACY COOPERATIVE | 313098 | INDEPENDENT PHARMACY COOPERATIVE | 2018 | first_quarter | PHA | Medicare CONTRACT YEAR 2019 POLICY AND TECHNICAL CHANGES comments. Support drug price concessions at the point of sale and limiting excessive pharmacy credentialing requirements. Oppose proposed changes to LIS dual-eligible Special Enrollment Period (SEP). Support S. 109/H.R. 592, the Pharmacy and Medically Underserved Areas Enhancement Act Support S.413/H.R. 1038, the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act. Ensure patient choice in Comprehensive Addiction and Recovery Act of 2016 lock-in provision. Support S. 413 / H.R. 1038 the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act" | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-04-10T13:38:22.923000-04:00 | |
| 2103364 | PENN AVENUE PARTNERS 86ef1dd4-c123-4efb-9eed-b7789cf3a157 | Q1 | PENN AVENUE PARTNERS | 400918672 | ALKERMES, INC. | 2018 | first_quarter | PHA | Regulatory and legislative issues impacting Alkermes. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-04-10T15:13:16.837000-04:00 | |
| 2103368 | PARRY, ROMANI, DECONCINI & SYMMS 013dc5ab-ff7b-4a42-8654-c0d3aa89cf2c | Q1 | PARRY, ROMANI, DECONCINI & SYMMS | 30792 | ROCK & ASSOCIATES | 2018 | first_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 12000 | 0 | 0 | 2018-04-10T15:14:19.350000-04:00 | |
| 2103988 | ACG ADVOCACY c2226eb9-0a23-49e5-9d27-d06f0c962f76 | Q1 | ACG ADVOCACY | 2057 | WALGREEN CO. | 2018 | first_quarter | PHA | Competition Policy Issues. Drug Pricing Policy Issues. | Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2018-04-11T13:36:39.750000-04:00 | |
| 2104567 | AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 2668e6bb-c5d2-4ed9-8145-8d2de3915fac | Q1 | AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION | 401103437 | AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION | 2018 | first_quarter | PHA | FDA Regulatory Review Drug Shortage | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 0 | 0 | 2018-04-12T10:29:16.830000-04:00 | ||
| 2104734 | AMERICAN CAPITOL GROUP d9970fd1-1d77-4e74-a278-7672390d491d | Q1 | AMERICAN CAPITOL GROUP | 305852 | CARDINAL HEALTH | 2018 | first_quarter | PHA | Issues Related to Distribution and Sale of Pharmaceutical and Medical Products and Services; | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 25000 | 0 | 0 | 2018-04-12T11:33:52.547000-04:00 | |
| 2104861 | ZHF CONSULTING LLC 8ad9f15f-8d8d-4890-8719-462c7f742768 | Q1 | ZHF CONSULTING LLC | 401103689 | MEDISCA, INC. | 2018 | first_quarter | PHA | Opioid crisis/alternative pain medication | HOUSE OF REPRESENTATIVES,SENATE | 22500 | 0 | 0 | 2018-04-12T12:40:23.653000-04:00 | |
| 2104892 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 2c54eed7-2c49-44e2-9f4a-2885b9f1d21d | Q1 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 3457 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 2018 | first_quarter | PHA | Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Communication with Congress on compounding. Letter to Senate leadership regarding H.R. 1628, American Health Care Act of 2017. Testified to Senate on 340B Drug Discount Program. Communicated with House and Senate offices on drug shortages. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 200000 | 0 | 0 | 2018-04-12T12:54:34.977000-04:00 | |
| 2104976 | MR. VINCENT A. PANVINI b66ae863-ab16-430a-81ee-612f0b0c6de4 | Q1 | MR. VINCENT A. PANVINI | 401008845 | PHRMA | 2018 | first_quarter | PHA | Medicare Part D | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2018-04-12T14:33:37.387000-04:00 | ||
| 2105006 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION eabbda3b-ed62-4229-9114-a5ccacc606e5 | Q1 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 29403 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2018 | first_quarter | PHA | Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). Oral Contraceptives H.R. 421/S. 93 - Allowing Greater Access to Safe and Effective Contraception Act of 2017. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections. Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of | 192000 | 0 | 0 | 2018-04-12T14:54:52.687000-04:00 | |
| 2105357 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 53162ac0-7c10-4d44-9488-274d36741fac | Q1 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 27478 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 2018 | first_quarter | PHA | Congressional Oversight of 340 B Program; Issues related to FDA implementation of The Drug Quality and Security Act related to the regulations of pharmacy compounding; Biosimilar naming; H.R. 421 Allowing Greater Access to Safe and Effective Contraception Act; H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017; HR 749, Lower Drug Costs through Competition Act | Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),Office of Personnel Management (OPM),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office | 400000 | 0 | 0 | 2018-04-13T11:26:29.100000-04:00 | |
| 2105858 | THE D MAJOR GROUP ceb7e3ab-0c5b-46e1-aa61-9b49c5c61a2f | Q1 | THE D MAJOR GROUP | 401103162 | ALLERGAN INC (FORMERLY ACTAVIS INC ) | 2018 | first_quarter | PHA | Monitor issues concerning bioequivalence standards for pharmaceuticals. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-04-14T14:38:35.083000-04:00 | |
| 2106345 | MCDERMOTT+ LLC e4485d4b-2981-48f7-86d4-bc638a9223a7 | Q1 | MCDERMOTT+ LLC | 401103287 | ALLIANCE FOR RURAL HOSPITAL ACCESS | 2018 | first_quarter | PHA | Amendments to Section 340B of the Public Health Service Act to gain eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-04-16T12:34:51.710000-04:00 | |
| 2106868 | CARD & ASSOCIATES, LLC 689aaf0b-4d75-4e49-b63c-754197bc0e0a | Q1 | CARD & ASSOCIATES, LLC | 84217 | AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) | 2018 | first_quarter | PHA | Educate Members on pharmacy contracting with pharmacy benefit managers H.R. 1316 Prescription Drug Price Transparency Act S. 637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act CMS-4182-P Technical Changes Defining Mail Order Pharmacy and Retail Pharmacy Comments-Final Regulations | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-04-16T16:35:58.037000-04:00 | |
| 2107059 | BROYDRICK & ASSOCIATES c83d2f76-2420-479c-bd92-38cc767933df | Q1 | BROYDRICK & ASSOCIATES | 7268 | TONIX PHARMACEUTICALS | 2018 | first_quarter | PHA | Funding for a new drug for PTSD. | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2018-04-16T18:06:12.847000-04:00 | |
| 2107161 | CONNECT 4 STRATEGIES, LLC 38635e5c-ae90-44c9-a67d-e24302eed149 | Q1 | CONNECT 4 STRATEGIES, LLC | 401103720 | OREXO US, INC. | 2018 | first_quarter | PHA | s916 Access to Emergency Medications Act | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-04-16T20:50:46.913000-04:00 | |
| 2107297 | PUBLIC CITIZEN d898d7b4-0d0f-447f-bc01-0843b3346b4e | Q1 | PUBLIC CITIZEN | 32362 | PUBLIC CITIZEN | 2018 | first_quarter | PHA | S. 771/HR 1776-Improving access to affordable Prescription Drugs act, S 2157-Drug Price transparency in Communications Act, S 2011/HR 4138-Medicare drug price negotiation act of 2017, S 1688-Empowering medicare seniors to negotiate drug prices of 2017, S 252-Medicare drug savings act of 2017, S 1369/HR 2974-Stop Price gouging act, S 124-Preserve access to affordable generics act, S 974/HR 2212-CREATES Act of 2017, S 495-Medical Innovation and Prize Fund Act, S 1131/HR 2439-FAIR drug pricing act, Over-the-counter Monograph Safety, Innovation, and Reform Act of 2018, HR 4117-Competitive DRUGS Act of 2017), HR 2051- FAST Generics Act of 2017), Prescription drug pricing, PACED Act, S 771/HR 1776 (Improving access to affordable prescription drugs act, S 1509/HR 1223 OPEN Act), S 1309-Stronger patents act, HR 5150 Protecting Medicare from excessive price increases act, S 2476-Expanding access to low cost generics act, S 637 (c-thru act), S 1348-SPIKE act, | HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Securities & Exchange Commission (SEC),SENATE,U.S. Trade Representative (USTR) | 60000 | 0 | 0 | 2018-04-17T09:35:20.940000-04:00 | |
| 2107420 | COVINGTON & BURLING LLP 83e753de-59af-4a91-a45d-ab95aa306d8a | Q1 | COVINGTON & BURLING LLP | 11195 | FLEXION THERAPEUTICS, INC. | 2018 | first_quarter | PHA | Education and support for public policies that promote the development, use, coverage and reimbursement of novel, non-opioid pain therapies, including FDA Opioid Sparing legislation. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2018-04-17T10:29:49.077000-04:00 | |
| 2107542 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER a68dbaa7-9a73-408e-81e6-497de617d7bb | Q1 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 312496 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 2018 | first_quarter | PHA | 340B drug pricing, PREA | Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office | 58456 | 0 | 0 | 2018-04-17T11:16:23.397000-04:00 | |
| 2108372 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 68d9e743-c290-4ed7-a3f9-62e6e53db9fe | Q1 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) | 28776 | HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) | 2018 | first_quarter | PHA | Ensuring Patient Access and Effective Enforcement Act (Public Law 114-145); Prescription Drug Abuse - General issues related to Rx drug abuse; Importation of Prescription Drugs (S 469, S 771, HR 1776, HR 1245, HR 934, HR 1480, S 92, S 64), Implementation of Public Law 113-54 (DSCSA) | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 302335 | 0 | 0 | 2018-04-17T15:05:58.887000-04:00 | |
| 2108394 | LUNGREN LOPINA LLC ccb487a0-4224-4ad5-8c13-1ea6ce491aa7 | Q1 | LUNGREN LOPINA LLC | 401103314 | AMPAC FINE CHEMICALS | 2018 | first_quarter | PHA | Fair treatment for US pharmaceutical ingredients | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2018-04-17T15:10:18.903000-04:00 | |
| 2108422 | THE MATHIS HARPLE GROUP e76604a1-1b21-4838-b60f-081caaf75549 | Q1 | THE MATHIS HARPLE GROUP | 322911 | PILMA | 2018 | first_quarter | PHA | Medicare Part D | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2018-04-17T15:14:35.563000-04:00 | |
| 2108445 | BLUECROSS BLUESHIELD OF TENNESSEE 4a7f03ed-3c12-4dc8-91d0-be272e3772f9 | Q1 | BLUECROSS BLUESHIELD OF TENNESSEE | 6440 | BLUECROSS BLUESHIELD OF TENNESSEE | 2018 | first_quarter | PHA | General pharmacy and pharmaceutical issues; Opioid Abuse; prescription drug pricing; generic drug issues. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-04-17T15:18:45.433000-04:00 | |
| 2108558 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. 760ebf70-709a-44c4-b9d1-a08e154ed2c8 | Q1 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. | 4653 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. | 2018 | first_quarter | PHA | Proposals relating to the regulation of direct-to-consumer prescription drug advertising H.R. 4385, Responsibility in Drug Advertising Act of 2017, which would prohibit DTC advertising of prescription drugs for the first three years after FDA approval | Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE,Treasury, Dept of | 440000 | 0 | 0 | 2018-04-17T15:47:04.057000-04:00 | |
| 2108634 | MANATT, PHELPS, AND PHILLIPS 276a30c9-98fa-4338-92f7-0f2f7d63e5c0 | Q1 | MANATT, PHELPS, AND PHILLIPS | 23645 | NEKTAR THERAPEUTICS | 2018 | first_quarter | PHA | FDA oversight of certain pain reliever products | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 72000 | 0 | 0 | 2018-04-17T15:57:54.783000-04:00 | |
| 2108642 | ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 2132b6e2-b94a-4f78-a8dd-c59e8b350bf0 | Q1 | ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM | 58534 | ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM | 2018 | first_quarter | PHA | HR 4392 To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; HR 4710 340B PAUSE Act Any provision(s) reducing or changing the 340B Drug Discount Program or benefits to hospitals limiting hospital access to the benefit and or improving or updating the program's guidelines. | HOUSE OF REPRESENTATIVES,SENATE | 380270 | 0 | 0 | 2018-04-17T16:00:57.910000-04:00 | |
| 2108733 | KOUNTOUPES DENHAM CARR & REID, LLC 2623ab75-8876-47bb-9bc4-c531d20e789a | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2018 | first_quarter | PHA | General issues related to over the counter pharmaceuticals. Issues related to draft legislation addressing the over the counter drug monograph process including H. R. 5333, the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018 and S. 2315, the Over-the-Counter Drug Safety, Innovation, and Reform Act. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-04-17T16:23:11.467000-04:00 | |
| 2108915 | COVINGTON & BURLING LLP b6b5259c-d843-4485-9487-141b27c9ed75 | Q1 | COVINGTON & BURLING LLP | 11195 | CELGENE CORPORATION | 2018 | first_quarter | PHA | Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051). | HOUSE OF REPRESENTATIVES,SENATE | 100000 | 0 | 0 | 2018-04-17T17:31:17.453000-04:00 | |
| 2108931 | BLUESTONE STRATEGIES, LLC e6f7f03d-90f5-442e-86de-f72606a8299f | Q1 | BLUESTONE STRATEGIES, LLC | 400658980 | AMERICA'S HEALTH INSURANCE PLANS (AHIP) | 2018 | first_quarter | PHA | Specialty Drugs and Prescription Drug Pricing | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-04-17T17:46:37.743000-04:00 | |
| 2108941 | BLUESTONE STRATEGIES, LLC f7797fd2-d59e-490b-a3eb-98a9f7cfc83c | Q1 | BLUESTONE STRATEGIES, LLC | 400658980 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2018 | first_quarter | PHA | Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-04-17T17:55:43.623000-04:00 | |
| 2109059 | THE METROHEALTH SYSTEM 0b45b472-043c-4d7f-b3c9-b69f88f945d7 | Q1 | THE METROHEALTH SYSTEM | 288236 | THE METROHEALTH SYSTEM | 2018 | first_quarter | PHA | 340B | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 7500 | 0 | 0 | 2018-04-17T18:39:33.160000-04:00 | |
| 2109147 | MCDERMOTT WILL & SCHULTE LLP bb4759dc-0059-4389-8fd0-7c8e17741b90 | Q1 | MCDERMOTT WILL & SCHULTE LLP | 24338 | MAXOR NATIONAL PHARMACY SERVICES, LLC | 2018 | first_quarter | PHA | Efforts to monitor and address pharmacy and drug pricing-related legislative and regulatory proposals, including, but not limited to, the 340B Program. | HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 40000 | 0 | 0 | 2018-04-17T19:32:41.017000-04:00 | |
| 2109454 | TAUZIN STRATEGIC NETWORKS 64b77f43-b1f1-490a-93b8-219aec4f9130 | Q1 | TAUZIN STRATEGIC NETWORKS | 400786367 | CAPTURERX | 2018 | first_quarter | PHA | Issues related to the 340b program | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-04-18T09:44:59.300000-04:00 | |
| 2109577 | MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) ec365db3-71a3-4822-b2c5-2e27b6fb2ba5 | Q1 | MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) | 400265214 | MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) | 2018 | first_quarter | PHA | Pricing, shortages, and safety issues | Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 122000 | 0 | 0 | 2018-04-18T10:13:15.947000-04:00 | |
| 2110026 | WINNING STRATEGIES WASHINGTON 64bb230d-b100-4ce8-9e83-e13296a82c9f | Q1 | WINNING STRATEGIES WASHINGTON | 50796 | KALEO | 2018 | first_quarter | PHA | Pharmaceutical drug development including epinephrine for anaphylaxis | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE | 40000 | 0 | 0 | 2018-04-18T11:58:11.280000-04:00 | |
| 2110040 | WAXMAN STRATEGIES 6dd5d93c-1371-405f-bcab-7f220671edfa | Q1 | WAXMAN STRATEGIES | 401103693 | 340B HEALTH | 2018 | first_quarter | PHA | Issues affecting the 340B drug pricing program; Pause Act | HOUSE OF REPRESENTATIVES,SENATE | 18750 | 0 | 0 | 2018-04-18T12:01:19.267000-04:00 | |
| 2110055 | WAXMAN STRATEGIES a2e06c8d-4f75-4c27-9712-966083f62c5e | Q1 | WAXMAN STRATEGIES | 401103693 | MEDICINES360 | 2018 | first_quarter | PHA | Issues impacting the 340B drug discount program; Pause Act | HOUSE OF REPRESENTATIVES | 0 | 0 | 2018-04-18T12:05:28.270000-04:00 | ||
| 2110339 | UC HEALTH 56f2d25e-e860-4b65-99ea-6ee99dc28ed3 | Q1 | UC HEALTH | 401103195 | UC HEALTH | 2018 | first_quarter | PHA | 340b program, drug pricing | Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2018-04-18T13:01:12.030000-04:00 | |
| 2110569 | KOUNTOUPES DENHAM CARR & REID, LLC d19349c7-dc06-43ef-9668-3f91d162dd8c | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | GLENMARK PHARMACEUTICALS, INC., USA | 2018 | first_quarter | PHA | General information about the company and the industry. Issues related to affordability and pricing of pharmaceuticals. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-04-18T13:41:01.537000-04:00 | |
| 2110643 | PRIME THERAPEUTICS bae21654-7898-47a2-8c66-36b16902af03 | Q1 | PRIME THERAPEUTICS | 400339576 | PRIME THERAPEUTICS | 2018 | first_quarter | PHA | S.778: Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). S.2554: "Patient Right to Know Drug Prices Act,"--provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2018-04-18T13:48:39.197000-04:00 | |
| 2110672 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES 22e7d6aa-c985-46da-827f-2fba1a0bf105 | Q1 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 26672 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 2018 | first_quarter | PHA | H.R. 1245/S. 469 The Affordable and Safe Prescription Drug Importation Act H.R. 1316 - Prescription Drug Price Transparency Act H.R. 749 Lower Drug Costs Through Competition H.R.2430/S. 934 - FDA Reauthorization Act of 2017 H.R. 4841 - Standardizing Electronic Prior Authorization for Safe Prescribing Act | Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 720000 | 0 | 0 | 2018-04-18T13:51:53.337000-04:00 | |
| 2110737 | FARRAGUT PARTNERS LLP 01c33024-c925-486e-8601-67a46ae53126 | Q1 | FARRAGUT PARTNERS LLP | 401103938 | AMERICAN SOCIETY OF INTERVENTIONAL PAIN PHYSICIANS | 2018 | first_quarter | PHA | Issues pertaining to Prescription Drug Monitoring programs. Public Health. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2018-04-18T14:04:41.500000-04:00 | |
| 2110816 | TARPLIN, DOWNS & YOUNG, LLC 031b59fd-6a49-4b0a-a7dd-1f5dbb3f808a | Q1 | TARPLIN, DOWNS & YOUNG, LLC | 304736 | BIOTECHNOLOGY INDUSTRY ORGANIZATION | 2018 | first_quarter | PHA | PL 114-255 - 21st Century Cures, implementation H.R. 2430 - FDA Reauthorization Act of 2017 ***, no specific bill(s), Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, Innovation | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 80000 | 0 | 0 | 2018-04-18T14:18:23.100000-04:00 | |
| 2110872 | FARRAGUT PARTNERS LLP 3b296b8e-1bf7-4238-b9cf-ff82c1ebf9a7 | Q1 | FARRAGUT PARTNERS LLP | 401103938 | GENENTECH | 2018 | first_quarter | PHA | Prescription Drug User Fee Act reathorization. Oversight of 340B drug discount program. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-04-18T14:29:57.310000-04:00 | |
| 2110885 | PENN AVENUE PARTNERS 78b4ccbc-ffb5-4c8d-a8ed-ebe16ed3b5a2 | Q1 | PENN AVENUE PARTNERS | 400918672 | PURDUE PHARMA L.P. | 2018 | first_quarter | PHA | Monitoring legislative and regulatory activities impacting the pharmaceutical industry. | SENATE | 60000 | 0 | 0 | 2018-04-18T14:32:05.810000-04:00 | |
| 2110901 | FARRAGUT PARTNERS LLP 050a1d28-2a7a-4aaa-9c36-924989bcddf2 | Q1 | FARRAGUT PARTNERS LLP | 401103938 | BLUE CROSS BLUE SHIELD ASSOCIATION | 2018 | first_quarter | PHA | Laboratory developed tests 21st Century Cures HR 6 21st Century Cures Act Introduced May 19, 2015 by Fred Upton (RMI) This bill amends the Public Health Service Act to reauthorize the National Institutes of Health (NIH) through FY2018. The NIH Innovation Fund is established to fund a strategic plan, early stage investigators, and highrisk, highreward research. The NIH may require scientific data to be shared if the research is fully funded by the NIH. The NIH and the Food and Drug Administration (FDA) must implement a system that allows further research on clinical trial data. The Centers for Disease Control and Prevention must expand surveillance of neurological diseases. The Council for 21st Century Cures is established to accelerate the discovery, development, and delivery of innovative cures, treatments, and preventive measures. The Department of Health and Human Services must monitor the use of antibacterial and antifungal drugs and resistance to these drugs | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE,Treasury, Dept of,White House Office | 50000 | 0 | 0 | 2018-04-18T14:35:17.500000-04:00 | |
| 2110916 | FARRAGUT PARTNERS LLP 2fcef8cf-71dd-4b1c-903d-9e097739f5c1 | Q1 | FARRAGUT PARTNERS LLP | 401103938 | COMMUNITY ONCOLOGY ALLIANCE | 2018 | first_quarter | PHA | Issues related to pharmacy benefit managers. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 80000 | 0 | 0 | 2018-04-18T14:38:28.907000-04:00 | |
| 2110938 | F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES 116e6d98-0aa0-4619-82f0-a54ae6f84062 | Q1 | F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES | 18411 | F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES | 2018 | first_quarter | PHA | S.1914 - Protecting Access to Diabetic Testing Supplies Act of 2017 | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 122279 | 0 | 0 | 2018-04-18T14:39:34.753000-04:00 | |
| 2110975 | TARPLIN, DOWNS & YOUNG, LLC 3efe7912-f425-485f-9add-a406a66c8296 | Q1 | TARPLIN, DOWNS & YOUNG, LLC | 304736 | HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) | 2018 | first_quarter | PHA | Importation of prescription drugs (S. 469, S. 771, H.R. 1776, H.R. 1245, H.R. 934, H.R. 1480, S. 92, S. 64) Opioid Drug Abuse - General issues related to opioid drug abuse Ensuring Patient Access and Effective Enforcement Act (PL 114-145) Implementation of Public Law 113-54 (DSCSA) | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2018-04-18T14:43:56.787000-04:00 | |
| 2111008 | FARRAGUT PARTNERS LLP 41c4311c-6caf-47ff-ad0f-c215d00845f9 | Q1 | FARRAGUT PARTNERS LLP | 401103938 | HERON THERAPEUTICS, INC. | 2018 | first_quarter | PHA | Issues related to opioid epidemic/specifically modifying rate setting for post surgical non opiods. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2018-04-18T14:46:09.867000-04:00 | |
| 2111082 | MERCURY PUBLIC AFFAIRS, LLC 39dc9dee-5385-4d37-94aa-f6e35d5efd34 | Q1 | MERCURY PUBLIC AFFAIRS, LLC | 70175 | KALISPELL REGIONAL HEALTHCARE | 2018 | first_quarter | PHA | Veteran pharmacy issues and polices | Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 30000 | 0 | 0 | 2018-04-18T14:56:50.997000-04:00 | |
| 2111233 | MERCURY PUBLIC AFFAIRS, LLC ee2c16b4-4c7f-48fc-a073-83d61462cecf | Q1 | MERCURY PUBLIC AFFAIRS, LLC | 70175 | MORRIS AND DICKSON | 2018 | first_quarter | PHA | IT Help RE Improper Prescriptions | Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS) | 20000 | 0 | 0 | 2018-04-18T15:26:25.573000-04:00 | |
| 2111320 | NOVO NORDISK INC. d2b3a93b-4ab7-41fc-83ff-761c5d32ad56 | Q1 | NOVO NORDISK INC. | 284790 | NOVO NORDISK INC. | 2018 | first_quarter | PHA | Issues related to P.L. 115-52 (H.R. 2430/S. 934) FDA Reauthorization Act of 2017 (Prescription Drug User Fee Act VI); H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act; H.R. 1776/S.771 Improving Access To Affordable Prescription Drugs Act; H.R. 4710, the 340B Protecting Access for the Underserved and Safety-Net Entities Act (340 PAUSE Act)and other issues related to 340B program | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE,Veterans Affairs, Dept of (VA) | 1460000 | 0 | 0 | 2018-04-18T15:33:23.187000-04:00 | |
| 2111583 | HANCE SCARBOROUGH 7d19af95-2caf-4171-8f77-ba1682a45f9d | Q1 | HANCE SCARBOROUGH | 17443 | ALLIANCE FOR PHARMACY COMPOUNDING | 2018 | first_quarter | PHA | Issues related to the regulation of pharmacy compounding. HR2871 Preserving Patient Access to Compounded Mediations Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2018-04-18T16:05:36.920000-04:00 | |
| 2111603 | PD FRAZER CONSULTING, INC. c0cd3b51-7678-4fa0-b43c-e51d24fe223c | Q1 | PD FRAZER CONSULTING, INC. | 65998 | CANADA INTERNATIONAL PHARMACY ASSOCIATION | 2018 | first_quarter | PHA | Support intent of H.R.1480 Safe and Affordable Drugs from Canada Act of 2017 Support intent of S.92 Safe and Affordable Drugs from Canada Act of 2017 Support intent of H.R. Affordable and Safe Prescription Drug Importation Act Support of S.469 Affordable and Safe Prescription Drug Importation Act | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2018-04-18T16:08:49.280000-04:00 | |
| 2111654 | AMERICAN VETERINARY MEDICAL ASSOCIATION 76ee0692-fcc4-4d55-92d8-e855177eeb10 | Q1 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 3630 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 2018 | first_quarter | PHA | H.R. 623, Fairness to Pet Owners Act; S.2434 Animal Drug and Animal Generic Drug User Fee Amendments of 2018 Anticipated legislative package related to the opioid crisis, principles of opioid use in veterinary medicine Docket No. FDA-2017-n-6502: Citation 82 FR 5872: Opioid Policy Steering Committee: Prescribing Intervention - Exploring a Strategy for Implementation: Public Hearing: Request for Comments Animal Drug and Animal Generic Drug User Fee Reauthorization | Agriculture, Dept of (USDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),SENATE,Treasury, Dept of | 200000 | 0 | 0 | 2018-04-18T16:13:08.190000-04:00 | |
| 2111711 | HANCE SCARBOROUGH 776f96f7-e6a2-4b44-bbcb-e0444efe0063 | Q1 | HANCE SCARBOROUGH | 17443 | TITAN PHARMACEUTICALS, INC. | 2018 | first_quarter | PHA | Medicare/Medicaid drug coverage,opioid addiction policy, S.2456 The CARA 2.0 Act of 2018. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2018-04-18T16:18:37.537000-04:00 | ||
| 2112392 | FTI GOVERNMENT AFFAIRS 40b124e8-2539-4540-bbb8-5211ceda66b0 | Q1 | FTI GOVERNMENT AFFAIRS | 401054971 | PERRIGO, INC. | 2018 | first_quarter | PHA | Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018", H.R. 5333. "Over-the-Counter Drug Safety, Innovation, and Reform Act", S. 2315. | HOUSE OF REPRESENTATIVES,SENATE | 150000 | 0 | 0 | 2018-04-18T19:40:26.347000-04:00 | |
| 2112399 | FTI GOVERNMENT AFFAIRS a4f00c6c-cf66-4c07-a1f4-234a323d4bd9 | Q1 | FTI GOVERNMENT AFFAIRS | 401054971 | PROFESSIONAL COMPOUNDING CENTERS OF AMERICA | 2018 | first_quarter | PHA | Implementation of The Drug Quality and Security Act, H.R.3204 (Public Law) ((USP/NF Monograph)). Monitor H.R.2871 "Preserving Patient Access to Compounded Medication Act of 2017. " | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-04-18T19:48:31.553000-04:00 | |
| 2112472 | DAIICHI SANKYO, INC. 97262875-0914-43b8-a421-34c7bdc7392b | Q1 | DAIICHI SANKYO, INC. | 316731 | DAIICHI SANKYO INC | 2018 | first_quarter | PHA | Discussions regarding opioid abuse Discussions regarding 340B drug discount program S.974,Creating and Restoring Equal Access To Equivalent Samples Act of 2017 (CREATES Act of 2017) Discussions regarding PBM patient assistance limitations | 130000 | 0 | 0 | 2018-04-18T22:33:09.697000-04:00 | ||
| 2112485 | ARENTFOX SCHIFF LLP 5ecd9341-5e3b-40d7-89bd-c61fc10c2e40 | Q1 | ARENTFOX SCHIFF LLP | 4208 | KEMPHARM, INC. | 2018 | first_quarter | PHA | FDA regulation of opioid abuse deterrent formulations | HOUSE OF REPRESENTATIVES,SENATE,White House Office | 30000 | 0 | 0 | 2018-04-18T23:38:18.590000-04:00 | |
| 2112528 | VAN SCOYOC ASSOCIATES 3c2189b9-c4f0-42eb-9b81-cfdbe277f460 | Q1 | VAN SCOYOC ASSOCIATES | 39837 | ZEBRA TECHNOLOGIES CORP. | 2018 | first_quarter | PHA | Public Law 113-54, Drug Quality and Security Act, Drug labeling implementation | HOUSE OF REPRESENTATIVES | 10000 | 0 | 0 | 2018-04-19T04:09:55.897000-04:00 | |
| 2112791 | IMPACT HEALTH POLICY PARTNERS f47c2ad9-00d3-4c83-ba75-bce6e2be394e | Q1 | IMPACT HEALTH POLICY PARTNERS | 401104696 | EXPRESS SCRIPTS | 2018 | first_quarter | PHA | Pharmacy benefits manager standards under the Medicare prescription drug program to further transparency of payment methodologies to pharmacies. Issues related to a pilot program in TRICARE that would establish Department of Defense (DoD) acquisition cost parity for prescription drugs obtained at community pharmacies. Drug reimbursement and general pharmacy related issues. S.637, Creating Transparency to Have Drug Rebates Unlocked (CTHRU) Act of 2017; issues related to transparency of pharmacy benefit managers (PBMs). | Centers For Medicare and Medicaid Services (CMS) | 30000 | 0 | 0 | 2018-04-19T07:04:16.873000-04:00 | |
| 2112969 | APOTEX CORP. 3db1af50-046d-455b-9105-d95df1410986 | Q1 | APOTEX CORP. | 310973 | APOTEX CORP. | 2018 | first_quarter | PHA | Federal policy related to Section 603, Applying the Medicaid additional rebate requirement to generics, of Public Law No 114-67, the Bipartisan Budget Act of 2015; and S. 2476, the Expanding Access to Low Cost Generics Act, provisions relating to pharmaceutical market blockages caused by "parked" Hatch-Waxman 180 day exclusivity periods. | HOUSE OF REPRESENTATIVES,SENATE | 160000 | 0 | 0 | 2018-04-19T09:24:22.117000-04:00 | |
| 2113205 | APOTEX CORP. 12c320df-fa90-4c25-8320-8363bacf0561 | 1A | APOTEX CORP. | 310973 | APOTEX CORP. | 2018 | first_quarter | PHA | Federal policy related to Section 603, Applying the Medicaid additional rebate requirement to generics, of Public Law No 114-67, the Bipartisan Budget Act of 2015; and S. 2476, the Expanding Access to Low Cost Generics Act, provisions relating to pharmaceutical market blockages caused by "parked" Hatch-Waxman 180 day exclusivity periods. | HOUSE OF REPRESENTATIVES,SENATE | 500000 | 0 | 0 | 2018-04-19T09:59:22.727000-04:00 | |
| 2113242 | MERCY HEALTH SYSTEM 0538dc67-60e7-4708-858b-9e88351c4c7d | Q1 | MERCY HEALTH SYSTEM | 40043344 | MERCY HEALTH SYSTEM | 2018 | first_quarter | PHA | Palliative Care 340 B Drug program Health Care Reform | HOUSE OF REPRESENTATIVES,SENATE | 8000 | 0 | 0 | 2018-04-19T10:04:54.337000-04:00 | |
| 2113501 | BROWN RUDNICK LLP 9d3cbd2f-ac68-4711-8062-f50aa98e2072 | Q1 | BROWN RUDNICK LLP | 287895 | HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC | 2018 | first_quarter | PHA | Public Law 113-54-Drug Quality and Security Act; S.469-The Affordable and Safe Prescription Drug Importation Act; H.R. 5267 relating to DEA controlled substances registration; Public Law 114-145-The Ensuring Patient Access and Effective Drug Enforcement Act; Issues relating to prescription drug abuse and diversion. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2018-04-19T10:29:00.680000-04:00 | |
| 2113507 | ALKERMES, INC. 18b30f15-b710-4196-baf3-b63740376faf | Q1 | ALKERMES, INC. | 400458235 | ALKERMES, INC. | 2018 | first_quarter | PHA | Public law #114-198, 21st Century Cures Opioid Implementation Awareness of outcomes data and the need for training on all medication assisted treatment | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),Veterans Affairs, Dept of (VA) | 1000000 | 0 | 0 | 2018-04-19T10:29:04.680000-04:00 | |
| 2113648 | MWW GROUP 453df78e-3ee0-4509-b8cd-0ed18dd163cd | Q1 | MWW GROUP | 26318 | UNITED PHARMACY PARTNERS, INC. (UPPI) | 2018 | first_quarter | PHA | Draft legislation regarding High Enriched Uranium (HEU) | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2018-04-19T10:43:31.907000-04:00 | |
| 2113703 | ELI LILLY AND COMPANY 2c463684-dc8c-4730-bf3f-08dfc814ed27 | Q1 | ELI LILLY AND COMPANY | 13392 | ELI LILLY AND COMPANY | 2018 | first_quarter | PHA | Hospital discounts; 340B program | Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR) | 1340000 | 0 | 0 | 2018-04-19T10:49:11-04:00 | |
| 2113757 | MASSACHUSETTS MEDICAL SOCIETY 8843ac1a-4cac-4224-ab89-61266a364a40 | Q1 | MASSACHUSETTS MEDICAL SOCIETY | 23975 | MASSACHUSETTS MEDICAL SOCIETY | 2018 | first_quarter | PHA | S. 771 - Improving Access to Affordable Prescription Drugs - Legislation that seeks to address prescription drug costs by increasing transparency and accountability, boosting access and affordability of key drugs, spurring innovation, and increasing choice and competition by allowing Medicare to negotiate the price of drugs, among other provisions. Efforts to require the manufacturers suggested retail price of prescription drugs in direct to consumer advertising of prescription drugs - no specific bill | Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE | 100000 | 0 | 0 | 2018-04-19T10:51:30.440000-04:00 | |
| 2114026 | ISEMAN & ASSOCIATES LLC d6287129-43e8-47dc-a1e4-3dc1a30e4177 | Q1 | ISEMAN & ASSOCIATES LLC | 401103582 | TICHENOR VENTURES, LLC | 2018 | first_quarter | PHA | Monitoring biotech legislation | HOUSE OF REPRESENTATIVES,SENATE | 12500 | 0 | 0 | 2018-04-19T11:13:17.937000-04:00 | |
| 2114358 | FLYNN & ASSOCIATES, INC. c82310df-0d3b-4cf6-98fc-315fbb3fb367 | Q1 | FLYNN & ASSOCIATES, INC. | 15020 | PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION | 2018 | first_quarter | PHA | Childrens Health Insurance Program Importation of drugs from Canada | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2018-04-19T11:49:31.767000-04:00 | |
| 2114453 | NELSON MULLINS RILEY & SCARBOROUGH a5c98d06-760b-4e0c-a5c3-99b38d925d8e | Q1 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | CASCADE HEMOPHILIA CONSORTIUM | 2018 | first_quarter | PHA | Issues related to 340B Drug Pricing Program | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2018-04-19T11:59:29.490000-04:00 | |
| 2114469 | NELSON MULLINS RILEY & SCARBOROUGH 26daff48-2929-4955-958c-2e9ec55cebf5 | Q1 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | HEMOPHILIA OF GEORGIA | 2018 | first_quarter | PHA | Issues related to the 340B Drug Pricing Program and biomedical research | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2018-04-19T12:01:40.757000-04:00 | |
| 2114488 | NATIONAL HOME INFUSION ASSOCIATION 4cf26742-ef0a-452e-8c3b-96637af35170 | Q1 | NATIONAL HOME INFUSION ASSOCIATION | 40047365 | NATIONAL HOME INFUSION ASSOCIATION | 2018 | first_quarter | PHA | Compounding pharmacy regulation - worked to ensure DQSA (Pub L. 113-54) is being properly implemented, specifically the draft memorandum of understanding for 503 A pharmacies and FDA inspections of 503A pharmacies. Lobbied for the inclusion of Department of Agriculture/FDA appropriations language regarding inspection authority and scope of the draft memorandum of understanding Lobbied on proper inspections of 503A pharmacies | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 130000 | 0 | 0 | 2018-04-19T12:02:53.180000-04:00 | |
| 2114619 | ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 637ac843-556d-42ce-be02-f5916c019d9f | Q1 | ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM | 58534 | ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM | 2018 | first_quarter | PHA | HR 4392 To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; HR 4710 340B PAUSE Act Any provision(s) reducing or changing the 340B Drug Discount Program or benefits to hospitals limiting hospital access to the benefit and or improving or updating the program's guidelines. | HOUSE OF REPRESENTATIVES,SENATE | 380270 | 0 | 0 | 2018-04-19T12:16:24.917000-04:00 | |
| 2114655 | ISEMAN & ASSOCIATES LLC 1987260a-fb09-482b-9028-9c68200d085d | Q1 | ISEMAN & ASSOCIATES LLC | 401103582 | TICHENOR VENTURES, LLC | 2018 | first_quarter | PHA | Monitoring biotech legislation | HOUSE OF REPRESENTATIVES,SENATE | 12500 | 0 | 0 | 2018-04-19T12:19:28.500000-04:00 | |
| 2114700 | OREGON HEALTH & SCIENCE UNIVERSITY a6551ea0-2e1f-4d3a-bfa5-6f51d50687d0 | Q1 | OREGON HEALTH & SCIENCE UNIVERSITY | 30291 | OREGON HEALTH & SCIENCE UNIVERSITY | 2018 | first_quarter | PHA | 340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2018-04-19T12:21:54.267000-04:00 | |
| 2114966 | KNIGHT CAPITOL CONSULTANTS b09ab41e-e510-43ae-80e8-36b56705c449 | Q1 | KNIGHT CAPITOL CONSULTANTS | 40036301 | EQUASHIELD, LLC | 2018 | first_quarter | PHA | Monitor issues related to Medical Device User Fee Act reauthorization contained in the Food and Drug Administration Reauthorization Act (PL 115-52) | Centers For Disease Control & Prevention (CDC),SENATE | 30000 | 0 | 0 | 2018-04-19T12:50:18.627000-04:00 | |
| 2115295 | KOUNTOUPES DENHAM CARR & REID, LLC dcf75b6b-4642-4222-ac69-c52ad0fa1fc4 | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CVS HEALTH | 2018 | first_quarter | PHA | General education about the pharmacy benefit manager/pharmacy industry, including S.637, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.974 and H. R. 2212, The CREATES Act. Proactive measures to curb opioid abuse. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),Office of the Vice President of the United States,SENATE,White House Office | 50000 | 0 | 0 | 2018-04-19T13:26:58.440000-04:00 | |
| 2115305 | FORBES-TATE c0be814f-c147-48cf-9b05-61b925f0adc5 | Q1 | FORBES-TATE | 400976792 | PHRMA | 2018 | first_quarter | PHA | Issues pertaining to Rx Drug pricing. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2018-04-19T13:28:05.973000-04:00 | |
| 2115345 | KNIGHT CAPITOL CONSULTANTS 47b6864e-795b-4d03-8db5-72e3c724bbc2 | Q1 | KNIGHT CAPITOL CONSULTANTS | 40036301 | INDIVIOR, INC. | 2018 | first_quarter | PHA | H.R. 5202/S. 916 Section 3: Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-04-19T13:31:29.850000-04:00 | |
| 2115467 | AKIN GUMP STRAUSS HAUER & FELD 4460ed7d-96c6-45c2-a41f-7234c48e4e7b | Q1 | AKIN GUMP STRAUSS HAUER & FELD | 682 | PHARMEDIUM SERVICES, LLC | 2018 | first_quarter | PHA | Drug Quality and Security Act, Pub. L. 113-54; FDA regulatory implementation of Section 503B of the Food, Drug and Cosmetic Act; FDA Pharmacy Compounding Advisory Committee; House & Senate Agriculture, FDA & Related Agency Appropriations bills; H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 100000 | 0 | 0 | 2018-04-19T13:44:51.247000-04:00 | |
| 2115636 | TARPLIN, DOWNS & YOUNG, LLC fa50cbaa-54d1-4c19-9e81-e6e0b1459553 | Q1 | TARPLIN, DOWNS & YOUNG, LLC | 304736 | PHRMA | 2018 | first_quarter | PHA | PL 114-255 - 21st Century Cures, implementation ***, no specific bill(s), prescription drug importation, import safety, supply chain integrity, Prescription Drug User Fee Act Fee Reauthorization and associated policies, user fee sequester, innovation | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2018-04-19T13:56:36.567000-04:00 | |
| 2115804 | AMERICAN PHARMACISTS ASSOCIATION b8fd7bb0-c886-4055-bb13-679735c9c5b3 | Q1 | AMERICAN PHARMACISTS ASSOCIATION | 3071 | AMERICAN PHARMACISTS ASSOCIATION | 2018 | first_quarter | PHA | HR 1038, S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act HR 1939 To amend title XVIII of the Social Security Act to ensure equal access of Medicare beneficiaries to community pharmacies in underserved areas as network pharmacies under Medicare prescription drug coverage, and for other purposes. HR 592, S 109 To amend title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services. HR 1480 Safe and Affordable Drugs from Canada Act of 2017 S 637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 HR 1586 To amend the Federal Food, Drug, and Cosmetic Act to ensure that liquid over-the-counter medications are packaged with appropriate dosage delivery devices and, in the case of such medications labeled for pediatric use, appropriate flow restrictors, and for other purposes. S 778 Prescription Drug Monitoring Act of 2017 HR 934 Personal Drug Importation Fairness Act of 2017 HR 421 Allowing Greater Access to Safe and Effective Contraception Act S 1079 Protecting Americans from Dangerous Opioids Act HR 2567 Access to Birth Control Act HR 2871 Preserving Patient Access to Compounded Medications Act of 2017 HR 2063 Opioid PACE Act of 2017 S 1003 A bill to amend title XIX of the Social Security Act to add standards for drug compendia for physician use for purposes of Medicaid payment for certain drugs, and for other purposes HR 1939/S 1044 Ensuring Seniors Access to Local Pharmacies Act of 2017 S 469 Affordable and Safe Prescription Drug Importation Act HR 3727 To amend title XVIII of the Social Security Act to include additional telehealth services for purposes of MA organization bids, and for other purposes. HR 2430 FDA Reauthorization Act of 2017 HR 3528/S 2460 Every Prescription Conveyed Securely Act | HOUSE OF REPRESENTATIVES,SENATE | 34000 | 0 | 0 | 2018-04-19T14:10:30.073000-04:00 | |
| 2116531 | 340B HEALTH 1809a348-8fdf-41ba-9abd-ff00943b8611 | Q1 | 340B HEALTH | 316434 | 340B HEALTH | 2018 | first_quarter | PHA | The 340B Drug Pricing Program, FY18 LHHS Appropriations, FY19 LHHS Appropriations, final 2018 Outpatient Prospective Payment System Rule, proposed and final rules regarding 340B ceiling price calculations and manufacturer civil monetary penalties, S.2312, S.2453, H.R.4710, H.R.4392 | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 269487 | 0 | 0 | 2018-04-19T14:54:56.703000-04:00 | |
| 2117291 | LEHIGH VALLEY HEALTH NETWORK 1c0e0f59-b9ab-4bfe-809b-5ef91d807149 | Q1 | LEHIGH VALLEY HEALTH NETWORK | 40041332 | LEHIGH VALLEY HEALTH NETWORK | 2018 | first_quarter | PHA | Supporting the continuation of 340B program | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2018-04-19T15:38:32.553000-04:00 | |
| 2117461 | UNITE HERE! 53d187d9-0dc4-420f-9e7e-36cefd00436e | Q1 | UNITE HERE! | 38984 | UNITE HERE! | 2018 | first_quarter | PHA | Advocating for the passage of: H.R. 1245-Affordable and Safe Prescription Drug Importation Act S. 469-Affordable and Safe Prescription Drug Importation Act H.R. 1776-Improving Access to Affordable Prescription Drugs Act Opposing the Nomination of Mr. Alex Azar to Secretary of HHS | AMTRAK - Natl Railroad Passenger Corporation,Federal Trade Commission (FTC),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Justice, Dept of (DOJ),Labor, Dept of (DOL),Natl Mediation Board,Pension Benefit Guaranty Corporation (PBGC),SENATE,State, Dept of (DOS) | 88758 | 0 | 0 | 2018-04-19T15:48:30.340000-04:00 | |
| 2117640 | MEHLMAN CONSULTING, INC. 0ac5e204-99ab-41f8-80f3-96814ee3d0bc | Q1 | MEHLMAN CONSULTING, INC. | 284950 | VIRTUS PHARMACEUTICALS LLC | 2018 | first_quarter | PHA | FDA Drug Approval | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-04-19T16:00:27.487000-04:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);